Klin Onkol 2021; 34(2): 151-152. DOI: 10.48095/ccko2021151.
There are some treatment options for metastatic and castration-resistant prostate cancer, and there is no single standardized treatment protocol today. In this group of patients, the chance of success in the treatment increased with the introduction of abiraterone, enzyalutamide/apalutamide, taxane chemotherapy (docetaxel, cabazitaxel) and immunotherapy (ipilimumab, sunitinib, cabozantinib, or xofigo). Although there was an increase in both disease-free and overall survival, resistance to these drugs developed within 1-2 years. Therefore, the search for new treatments has continued [1–3]. In recent years, 223radium and 177lutetium (177Lu) prostate-specific membrane antigen (PSMA) have been shown to provide effective treatment of metastatic and castration-resistant prostate cancer with the application of radiopharmaceuticals containing ionizing radiation. The use of 177Lu-PSMA treatment, which is a radionuclide treatment, is increasing day by day [4–6].....
